PortfoliosLab logo
MRNA vs. CHTR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MRNA and CHTR is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.4

Performance

MRNA vs. CHTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and Charter Communications, Inc. (CHTR). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%200.00%December2025FebruaryMarchAprilMay
49.68%
24.88%
MRNA
CHTR

Key characteristics

Sharpe Ratio

MRNA:

-1.08

CHTR:

1.28

Sortino Ratio

MRNA:

-2.14

CHTR:

2.06

Omega Ratio

MRNA:

0.74

CHTR:

1.26

Calmar Ratio

MRNA:

-0.79

CHTR:

0.76

Martin Ratio

MRNA:

-1.18

CHTR:

4.98

Ulcer Index

MRNA:

63.45%

CHTR:

10.41%

Daily Std Dev

MRNA:

68.28%

CHTR:

40.75%

Max Drawdown

MRNA:

-94.94%

CHTR:

-68.99%

Current Drawdown

MRNA:

-94.25%

CHTR:

-51.98%

Fundamentals

Market Cap

MRNA:

$10.68B

CHTR:

$54.04B

EPS

MRNA:

-$8.73

CHTR:

$35.84

PEG Ratio

MRNA:

0.00

CHTR:

0.41

PS Ratio

MRNA:

3.23

CHTR:

0.98

PB Ratio

MRNA:

1.01

CHTR:

3.33

Total Revenue (TTM)

MRNA:

$3.16B

CHTR:

$55.14B

Gross Profit (TTM)

MRNA:

$1.66B

CHTR:

$31.64B

EBITDA (TTM)

MRNA:

-$3.20B

CHTR:

$21.61B

Returns By Period

In the year-to-date period, MRNA achieves a -33.04% return, which is significantly lower than CHTR's 15.02% return.


MRNA

YTD

-33.04%

1M

10.87%

6M

-48.00%

1Y

-77.73%

5Y*

-10.71%

10Y*

N/A

CHTR

YTD

15.02%

1M

16.54%

6M

4.90%

1Y

48.25%

5Y*

-4.81%

10Y*

8.14%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MRNA vs. CHTR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNA
The Risk-Adjusted Performance Rank of MRNA is 66
Overall Rank
The Sharpe Ratio Rank of MRNA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 22
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 33
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 55
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 1919
Martin Ratio Rank

CHTR
The Risk-Adjusted Performance Rank of CHTR is 8484
Overall Rank
The Sharpe Ratio Rank of CHTR is 8888
Sharpe Ratio Rank
The Sortino Ratio Rank of CHTR is 8686
Sortino Ratio Rank
The Omega Ratio Rank of CHTR is 8383
Omega Ratio Rank
The Calmar Ratio Rank of CHTR is 7878
Calmar Ratio Rank
The Martin Ratio Rank of CHTR is 8686
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MRNA vs. CHTR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Charter Communications, Inc. (CHTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for MRNA, currently valued at -1.08, compared to the broader market-2.00-1.000.001.002.003.00
MRNA: -1.08
CHTR: 1.28
The chart of Sortino ratio for MRNA, currently valued at -2.14, compared to the broader market-6.00-4.00-2.000.002.004.00
MRNA: -2.14
CHTR: 2.06
The chart of Omega ratio for MRNA, currently valued at 0.74, compared to the broader market0.501.001.502.00
MRNA: 0.74
CHTR: 1.26
The chart of Calmar ratio for MRNA, currently valued at -0.79, compared to the broader market0.001.002.003.004.005.00
MRNA: -0.79
CHTR: 0.76
The chart of Martin ratio for MRNA, currently valued at -1.18, compared to the broader market-40.00-30.00-20.00-10.000.0010.0020.00
MRNA: -1.18
CHTR: 4.98

The current MRNA Sharpe Ratio is -1.08, which is lower than the CHTR Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of MRNA and CHTR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00December2025FebruaryMarchAprilMay
-1.08
1.28
MRNA
CHTR

Dividends

MRNA vs. CHTR - Dividend Comparison

Neither MRNA nor CHTR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MRNA vs. CHTR - Drawdown Comparison

The maximum MRNA drawdown since its inception was -94.94%, which is greater than CHTR's maximum drawdown of -68.99%. Use the drawdown chart below to compare losses from any high point for MRNA and CHTR. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%December2025FebruaryMarchAprilMay
-94.25%
-51.98%
MRNA
CHTR

Volatility

MRNA vs. CHTR - Volatility Comparison

The current volatility for Moderna, Inc. (MRNA) is 17.89%, while Charter Communications, Inc. (CHTR) has a volatility of 19.02%. This indicates that MRNA experiences smaller price fluctuations and is considered to be less risky than CHTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%December2025FebruaryMarchAprilMay
17.89%
19.02%
MRNA
CHTR

Financials

MRNA vs. CHTR - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and Charter Communications, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B14.00B20212022202320242025
107.00M
13.74B
(MRNA) Total Revenue
(CHTR) Total Revenue
Values in USD except per share items